Dossier
obefazimod
Coverage of obefazimod in the Nexus archive.
- STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
Abivax released additional data on its experimental ulcerative colitis drug obefazimod to address safety concerns, leading to a 25% rise in U.S.-listed shares. The drug showed strong efficacy in a maintenance trial, but prior cancer cases among participants had raised safety risks.
- STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax's experimental drug obefazimod showed strong efficacy in a Phase 3 trial for ulcerative colitis, with over 50% of participants achieving clinical remission. However, the company's shares dropped after reporting cancer cases among treated patients, raising safety concerns.